Mabpharm Limited (HK:2181) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Mabpharm Limited has announced structural changes to its leadership team, effective July 10, 2024, including the appointment of Mr. Cen Jialin as a non-executive Director, Dr. Tao Qian as an independent non-executive Director, and the re-designation and promotion of Dr. Qian Weizhu to executive Director and vice president. Additionally, Mr. Li Yunfeng transitions from the CFO to a vice president role. These appointments and re-designations reflect the company’s strategic adjustments in its executive team.
For further insights into HK:2181 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue